Record Nr.	UNISA996199123803316
Titolo	Vascular complications of diabetes [[electronic resource]] : current issues in pathogenesis and treatment / / editor, Richard Donnelly ; associate editor, Edward Horton
Pubbl/distr/stampa	Malden, Mass., : Blackwell Pub., 2005
ISBN	1-281-32237-7 9786611322373 0-470-75150-9 0-470-75149-5
Edizione	[2nd ed.]
Descrizione fisica	1 online resource (242 p.)
Altri autori (Persone)	DonnellyRichard <1960-> HortonEdward S
Disciplina	616.1/3
Soggetti	Diabetic angiopathies
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di bibliografia	Includes bibliographical references and index.
Nota di contenuto	The public health impact of the diabetes epidemic Risk factors Diabetic nephropathy Coronary heart disease and diabetes Diabetes and cerebrovascular disease Erectile dysfunction Evidence-based interventions to prevent or retard vascular complications Classification and clinical features of neuropathy Pathophsiology [sic] of diabetic neuropathy Epidemiology and natural history of DPN Detections/screenings/assessment Foot ulceration and charcot arthropathy Treatment options Management guidelines for diabetic peripheral neuropathy and foot ulceration Diabetic retinopathy: epidemiology and risk factors Classification and diagnosis of diabetic retinopathy Diabetic maculopathy Proliferative diabetic retinopathy Non-retinal diabetic ocular complications Pathophysiology & potential targets for therapeutic intervention Protein kinase C PKC activation & vascular permeability Role of PKC activation in cardiovascular and renal complications of diabetes Experimental pharmacology using isoform-selective PKC inhibitors Clinical trials with ruboxistaurin.
Sommario/riassunto	Diabetes has reached epidemic proportions, and the cardiovascular

1.

complications of diabetes are life-threatening and disabling. This book is unique in providing a simple explanation of the biochemical role of PKC in diabetes complications, which allows clinicians to understand why PKC inhibitors (in development) are an exciting prospect for future treatment to slow progression of eye & foot complications. New features of this Second Edition include:Updated throughout to reflect the impact of recent major clinical trials on current clinical practice Include